Budesonide, Formoterol Fumarate Dihydrate

7 trials 1 recruiting RRespiratory

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

1 Recruiting

5 Completed trials

3 Sponsors

17 Countries

Phase III

Phase IV

Phase III: 6 Phase IV: 1

Oversight events:

1 serious breach 1 urgent safety measure 1 corrective measure across 2 trials

View oversight register →

Indications tested

Sponsors using this IMP

AstraZeneca AB 4 Areteia Therapeutics Inc. 2 Hospices Civils De Lyon 1

All trials

7 total

A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Not authorised

2023-503693-20-00 Phase III 1 country Areteia Therapeutics Inc.
A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinoph… Recruiting

2024-515162-13-00 Phase III 7 countries AstraZeneca AB
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended

2023-503693-20-01 Phase III 9 countries Areteia Therapeutics Inc.
Symptoms control and adhErenCe assessment during treatment with mepolizUmab new pREfilled devices. SECURE Ended

2022-501029-19-00 Phase IV 1 country Hospices Civils De Lyon
Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler in Patients with Inadequately Controlled Asthma Ended

2024-513568-24-00 Phase III 3 countries AstraZeneca AB
"A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with … Ended

2023-505787-11-00 Phase III 6 countries AstraZeneca AB
A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with S… Ended

2023-505786-88-00 Phase III 5 countries Astrazeneca AB

Showing 1–7 of 7 trials

← All drugs A–Z